Relation of Blood Omentin-1 and Some Biochemical Parameters With Body Mass Index in Patients of Nonalcoholic Fatty Liver Disease


  • Haneen Hassan Ali
  • Khalid Shaalan Sahab



Omentin-1, liver functions parameters, lipids profiles, C-RP and NAFLD.


Nonalcoholic fatty liver disease (NAFLD) is a condition of increasing fat in liver of individuals
who do not consume significant amount of alcohol. The study aimed to estimate Omentin-1,
insulin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline
phosphatase (ALk) , albumin, globulin, total protein, CRP, Triglyceride (TG), total cholesterol
(TC), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density
lipoprotein (VLDL) in the serum of NAFLD patients, and find the relationship of variation in
omentin-1 and Some Biochemical Parameters with body mass index(BMI) in Patients of
NAFLD And comparing them with to the healthy ones.
Ninety people were involved in this study (60 were patients with NAFLD and 30 healthy
individuals) from Al-Muqdudia General Hospital in Diyala province, Iraq, during the period
1/10/2021 to 30/12/2021. The ELISA Kit was used to detect serum omentin-1. A rapid
quantitative assay HS-INSULIN-CHECK-1 is used to estimate the of insulin. The CRP-latex is
a slide agglutination test for the quantitive and semi-quantitive detection of C-reacive protein
(CRP) in human serum. in serum AST, ALT, ALP, Albumin Globulin, Total Protein, TG, TC
and HDL tests were assessed using an Semi automated spectrophotometer (Humalyzer Primus).
Serum omentin-1 levels were higher in patients than in healthy subjects with significant
differences (p<0.05). Serum levels of ALT , AST and CPR were increased significantly in patients compared with controls (p<0.05). The results ALP, LDL, albumin, total protein, insulin
,and globulin showed no significant increase(p>0.05) in patients compared with controls. Serum
cholesterol, TG and VLDL were significantly (p<0.05) elevated in patients in comparison to
controls group, while HDL levels were decreased non significantly (p>0.05). Omentin-1 was
positively correlated with cholesterol, TG, LDL, VLDL, insulin, ALP and globulin BMI. Serum
omentin-1 concentrations were negatively correlated with HDL, ALT, AST, albumin and
protein. All these correlations between serum omentin-1 and biochemical parameters were
without significant different (p>0.05). The omentin-1 showed not significant association with
the anthropometries measurements.


Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73-84.

Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., ... & Sanyal, A. J. (2018). The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1), 328-357.

Rabiee, S., Nezhadali, M., & Hedayati, M. (2018). Association of Adiponectin Gene rs2241766 Polymorphism with non-Alcoholic Fatty Liver Disease in an Iranian Population. Armaghane-danesh, YUMSJ 1397; 23: 476-487.‏

Yki-Järvinen, H. (2014). Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. The lancet Diabetes & endocrinology, 2(11), 901-910.

Tilg, H., & Diehl, A. M. (2000). Cytokines in alcoholic and nonalcoholic steatohepatitis. New England Journal of Medicine, 343(20), 1467-1476.

Gastaldelli, A., Miyazaki, Y., Pettiti, M., Matsuda, M., Mahankali, S., Santini, E., ... & Ferrannini, E. (2002). Metabolic effects of visceral fat accumulation in type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism, 87(11), 5098-5103.

Fruhbeck, G., Gómez-Ambrosi, J., Muruzábal, F. J., & Burrell, M. A. (2001). The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. American Journal of Physiology-Endocrinology and Metabolism, 280(6), E827-E847.

Giralt, M., Cereijo, R., & Villarroya, F. (2015). Adipokines and the endocrine role of adipose tissues. Metabolic control, 265-282.‏

Koleva, D. I., Orbetzova, M. M., & Atanassova, P. K. (2013). Adipose tissue hormones and appetite and body weight regulators in insulin resistance. Folia Med (Plovdiv), 55(1), 25-32.

Bekaert, M., Verhelst, X., Geerts, A., Lapauw, B., & Calders, P. (2016). Association of recently described adipokines with liver histology in biopsy‐proven non‐alcoholic fatty liver disease: a systematic review. Obesity reviews, 17(1), 68-80.

Fain, J. N., Sacks, H. S., Buehrer, B., Bahouth, S. W., Garrett, E., Wolf, R. Y., ... & Madan, A. K. (2008). Identification of omentin mRNA in human epicardial adipose tissue: comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. International Journal of Obesity, 32(5), 810-815.‏

Aliasghari, F., Izadi, A., Jabbari, M., Imani, B., Gargari, B. P., Asjodi, F., & Ebrahimi, S. (2018). Are vaspin and omentin-1 related to insulin resistance, blood pressure and inflammation in NAFLD patients?. Journal of Medical Biochemistry, 37(4), 470.

Kohan, L., Safarpur, M., & Abdollahi, H. (2016). Omentin-1 rs2274907 and resistin rs1862513 polymorphisms influence genetic susceptibility to nonalcoholic fatty liver disease. Molecular Biology Research Communications, 5(1), 11.

Yang, R. Z., Lee, M. J., Hu, H., Pray, J., Wu, H. B., Hansen, B. C., ... & Gong, D. W. (2006). Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. American journal of physiology-endocrinology and metabolism, 290(6), E1253-E1261.

Zhang, Y., Hao, Z., Shen, X., Zhou, J., & Zhang, L. (2016). Circulating levels of adipocytokines omentin-1 and adiponectin in patients with bladder cancer. Int J Clin Exp Pathol, 9(11), 11718-11726.

Montazerifar, F., Bakhshipour, A. R., Karajibani, M., Torki, Z., & Dashipour, A. R. (2017). Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences, 22‏.

Halabis, M., Dziedzic, M., Warchulinska, J., Kaznowska-Bystryk, I., & Solski, J. (2015). Omentin-a new adipokine with many roles to play. Curr Issues Pharm Med Sci, 28(3), 176-180.

Lesná, J., Tichá, A., Hyšpler, R., Musil, F., Bláha, V., Sobotka, L., ... & Šmahelová, A. (2015). Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction. Nutrition & diabetes, 5(11), e183-e183.

Gürsoy, G., Kırnap, N. G., Eşbah, O., Acar, Y., Demirbaş, B., Akçayöz, S., & Öztürk, A. (2010). The relationship between plasma omentin-1 levels and insulin resistance in newly diagnosed type 2 diabetıc women. Clin Rev Opinions, 2(4), 49-54.

El‐Mesallamy, H. O., El‐Derany, M. O., & Hamdy, N. M. (2011). Serum omentin‐1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabetic Medicine, 28(10), 1194-1200.

Shima, T., Seki, K., Umemura, A., Ogawa, R., Horimoto, R., Oya, H., ... & Okanoue, T. (2015). Influence of lifestyle‐related diseases and age on the development and progression of non‐alcoholic fatty liver disease. Hepatology Research, 45(5), 548-559.

Gan, L., Chitturi, S., & Farrell, G. C. (2011). Mechanisms and implications of age-related changes in the liver: nonalcoholic fatty liver disease in the elderly. Current gerontology and geriatrics research, 2011.

Frith, J., Day, C. P., Henderson, E., Burt, A. D., & Newton, J. L. (2009). Non-alcoholic fatty liver disease in older people. Gerontology, 55(6), 607-613.

Wong, V. W. S., Wong, G. L. H., Chan, R. S. M., Shu, S. S. T., Cheung, B. H. K., Li, L. S., ... & Chan, H. L. Y. (2018). Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. Journal of hepatology, 69(6), 1349-1356.

Bazick, J., Donithan, M., Neuschwander-Tetri, B. A., Kleiner, D., Brunt, E. M., Wilson, L., ... & Loomba, R. (2015). Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes care, 38(7), 1347-1355.

Ali, A. H., Petroski, G. F., Diaz-Arias, A. A., Al Juboori, A., Wheeler, A. A., Ganga, R. R., ... & Ibdah, J. A. (2021). A Model Incorporating Serum Alkaline Phosphatase for Prediction of Liver Fibrosis in Adults with Obesity and Nonalcoholic Fatty Liver Disease. Journal of Clinical Medicine, 10(15), 3311.

Verrijken, A., Francque, S., Mertens, I., Talloen, M., Peiffer, F., & Van Gaal, L. (2010). Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. International journal of obesity, 34(5), 899-907.

Allard, J. P., Aghdassi, E., Mohammed, S., Raman, M., Avand, G., Arendt, B. M., ... & Heathcote, J. E. (2008). Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. Journal of hepatology, 48(2), 300-307.

Papatheodoridis, G. V., Goulis, J., Christodoulou, D., Manolakopoulos, S., Raptopoulou, M., Andrioti, E., ... & Tsianos, E. (2007). High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity. European journal of gastroenterology & hepatology, 19(4), 281-287.

Khamseh, M. E., Malek, M., Abbasi, R., Taheri, H., Lahouti, M., & Alaei-Shahmiri, F. (2021). Triglyceride glucose index and related parameters (triglyceride glucose-body mass index and triglyceride glucose-waist circumference) identify nonalcoholic fatty liver and liver fibrosis in individuals with overweight/obesity. Metabolic Syndrome and Related Disorders, 19(3), 167-173.

Altlparmak, E., Köklü, S., Yallnklllc, M., Yüksel, O., Cicek, B., Kayacetin, E., & Sahin, T. (2005). Viral and host causes of fatty liver in chronic hepatitis B. World journal of gastroenterology: WJG, 11(20), 3056.

Mirhafez, S. R., Azimi-Nezhad, M., Dehabeh, M., Hariri, M., Naderan, R. D., Movahedi, A., ... & Sahebkar, A. (2021). The effect of curcumin phytosome on the treatment of patients with non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled trial. In Pharmacological Properties of Plant-Derived Natural Products and Implications for Human Health (pp. 25-35). Springer, Cham.

Al-Hussein Hassan, H. A., Salman Dawood, D., & Jawad Hussein, R. (2021). Relationship between G3BP and R4BP with Some Biochemical Parameters in Iraqi Patients with Nonalcoholic Fatty Liver Disease. Medico-Legal Update, 21(3).

Sabry, M., Youssef, T., Shaker, M., Salama, M. M., Assem, N., & Anwar, C. A. (2021). Portal venous and hepatic artery hemodynamic variation in non-alcoholic fatty liver disease. Egyptian Liver Journal, 11(1), 1-6.

Adiels, M., Taskinen, M. R., & Borén, J. (2008). Fatty liver, insulin resistance, and dyslipidemia. Current diabetes reports, 8(1), 60-64.

Tutunchi, H., Naeini, F., Ebrahimi‐mameghani, M., Mobasseri, M., Naghshi, S., & Ostadrahimi, A. (2021). The association of the steatosis severity, NAFLD fibrosis score and FIB‐4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross‐sectional study. International journal of clinical practice, 75(6), e14131.

Agrawal, R., Mishra, S., Dixit, V. K., & Rai, S. (2009). Association of non-alcoholic fatty liver disorder with obesity. Indian J Prev Soc Med, 40, 126-129.

Wah-Kheong, C., & Khean-Lee, G. (2013). Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease. Hepatology international, 7(1), 65-71.

Xu, C. F., Yu, C. H., Li, Y. M., Xu, L., Du, J., & Shen, Z. (2007). Association of the frequency of peripheral natural killer T cells with nonalcoholic fatty liver disease. World journal of gastroenterology: WJG, 13(33), 4504.

Zhang, Z., Wang, J., & Wang, H. (2018). Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus. Experimental and therapeutic medicine, 15(3), 2936-2940.

Fujii, H., Kawada, N., & Japan Study Group of NAFLD (JSG-NAFLD). (2020). The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. International Journal of Molecular Sciences, 21(11), 3863.

Tricò, D., Galderisi, A., Mari, A., Polidori, D., Galuppo, B., Pierpont, B., ... & Caprio, S. (2020). Intrahepatic fat, irrespective of ethnicity, is associated with reduced endogenous insulin clearance and hepatic insulin resistance in obese youths: A cross‐sectional and longitudinal study from the Y ale P ediatric NAFLD cohort. Diabetes, Obesity and Metabolism, 22(9), 1628-1638.

Yilmaz, Y., Yonal, O., Kurt, R., Alahdab, Y. O., Eren, F., Ozdogan, O., ... & Avsar, E. (2011). Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scandinavian journal of gastroenterology, 46(1), 91-97.

Eisinger, K., Krautbauer, S., Wiest, R., Karrasch, T., Hader, Y., Scherer, M. N., ... & Buechler, C. (2013). Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. European Journal of Clinical Investigation, 43(9), 926-932.

Montazerifar, F., Bakhshipour, A. R., Karajibani, M., Torki, Z., & Dashipour, A. R. (2017). Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences, 22.

Alizadeh, S., Mirzaei, K., Mohammadi, C., Keshavarz, S. A., & Maghbooli, Z. (2017). Circulating omentin-1 might be associated with metabolic health status in different phenotypes of body size. Archives of endocrinology and metabolism, 61, 567-574

Turkkan, E., Dag, H., Dikker, O., Dag, N. C., Kacar, A., & Sazak, S. (2021). Omentin-1 Levels and Non-alcoholic Fatty Liver Disease in Obese Adolescents. Iranian Journal of Pediatrics, 31(5).

Jimba, S., Nakagami, T., Takahashi, M., Wakamatsu, T., Hirota, Y., Iwamoto, Y., & Wasada, T. J. D. M. (2005). Prevalence of non‐alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetic medicine, 22(9), 1141-1145.

Rafiq, N., Bai, C., Fang, Y. U. N., Srishord, M., McCullough, A., Gramlich, T., & Younossi, Z. M. (2009). Long-term follow-up of patients with nonalcoholic fatty liver. Clinical Gastroenterology and Hepatology, 7(2), 234-238.‏

Foroughi, M., Maghsoudi, Z., Khayyatzadeh, S., Ghiasvand, R., Askari, G., & Iraj, B. (2016). Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. Advanced Biomedical Research, 5 .

Cardoso-Saldaña, G. C., Medina-Urrutia, A. X., Posadas-Romero, C., Juárez-Rojas, J. G., Jorge-Galarza, E., Vargas-Alarcón, G., & Posadas-Sánchez, R. (2015). Fatty liver and abdominal fat relationships with high C-reactive protein in adults without coronary heart disease. Annals of Hepatology, 14(5), 658-665.

Hadizadeh, F., Faghihimani, E., & Adibi, P. (2017). Nonalcoholic fatty liver disease: Diagnostic biomarkers. World journal of gastrointestinal pathophysiology, 8(2), 11.




How to Cite

Hassan Ali, H. ., & Shaalan Sahab, K. . (2024). Relation of Blood Omentin-1 and Some Biochemical Parameters With Body Mass Index in Patients of Nonalcoholic Fatty Liver Disease. Academic Science Journal, 2(1), 179–199.